This heralds a new public-private partnership to improve clinical trial infrastructure to facilitate the development of new drugs for children in Europe.
The six-year project, comprised of a multidisciplinary public-private consortium, brings together key stakeholders across academia and industry.
Led by PENTA, the c4c consortium aims to enhance the competitiveness of Europe as a critical region for developing medicines for children by using existing expertise, patient access and developing common processes to be applied to disease natural history studies, registries, studies of new therapies and comparisons of existing therapies.
The consortium is a novel collaboration between academic and private sectors, including 33 academic and 10 industry partners from 20 European countries, more than 50 third parties and around 500 affiliated partners. Read the full press release on the brand new c4c website.